Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03751436 · ClinicalTrials.gov registry record · Phase 1
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03751436 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 10 participants.
The verdict
NCT03751436, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This phase Ib/II trial studies the side effects and best dose of venetoclax when given together with enzalutamide and to see how well they work in treating patients with castration resistant prostate cancer that has spread to other places in the body. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, may lessen the amount of androgens made by the body. Venetoclax may target a special group of prostate cancer cells that is known to lead to resistance to treatment. Giving enzalutamide and venetoclax may work better in treating patients with castration resistant prostate cancer.
Interventions
- DRUG Venetoclax
- DRUG Enzalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-08-02 |
| Est. Completion | 2023-08-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03751436
The ClinicalTrials.gov registry entry for NCT03751436 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Venetoclax is the first listed.
NCT03751436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03751436 about?
NCT03751436 is a clinical study titled "Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer". This phase Ib/II trial studies the side effects and best dose of venetoclax when given together with enzalutamide and to see how well they work in treating patients with castration resistant prostate cancer that has spread to other places in the body. Androgens can cause the growth of prostate cance...
What is the current status of trial NCT03751436?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-08-02. Estimated completion is 2023-08-11.
What interventions are being tested in trial NCT03751436?
The interventions under investigation include: Venetoclax (DRUG), Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT03751436?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.